Brexit brings a lot of challenging problems, some easier to solve, others harder. One of them is pharmacovigilance. How will it be affected by Brexit? The European database EudraVigilance for example, which is used to record reports on adverse drug reactions, could possibly no longer be available to British authorities after Brexit. However, no one knows exactly what kind of Brexit we will get, and it is therefore difficult to say what effects it will have. Sarah Hall, President of the non-profit organization PIPA, has nevertheless looked into the various Brexit scenarios and published her assessment of the effects of the respective scenarios on pharmacovigilance in this article on healtheuropa.eu.
Comments are closed.